FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897636215> ?p ?o ?g. }

• W2897636215 endingPage "980" @default.
• W2897636215 startingPage "969" @default.
• W2897636215 abstract "We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14.3 months for placebo+BR (hazard ratio [HR] [95% CI], 0.206 [0.159-0.265]; P < 0.0001); 36-month PFS rates were 68.0% versus 13.9%, respectively. The results are consistent with the primary analysis findings (HR = 0.203, as assessed by independent review committee, with 17-month median follow-up). Median overall survival was not reached in either arm; HR (95% CI) for ibrutinib+BR versus placebo: 0.652 (0.454-0.935; P = 0.019). Minimal residual disease (MRD)-negative response rates were 26.3% for ibrutinib+BR and 6.2% for placebo+BR (P < 0.0001). Incidence of treatment-emergent adverse events (including grades 3-4) were generally consistent with the initial HELIOS report. These long-term data support improved survival outcomes and deepening responses with ibrutinib+BR compared with BR in relapsed CLL/SLL." @default.
• W2897636215 created "2018-10-26" @default.
• W2897636215 creator A5000379341 @default.
• W2897636215 creator A5003034197 @default.
• W2897636215 creator A5005446802 @default.
• W2897636215 creator A5010286156 @default.
• W2897636215 creator A5011217358 @default.
• W2897636215 creator A5017461150 @default.
• W2897636215 creator A5018718373 @default.
• W2897636215 creator A5025529105 @default.
• W2897636215 creator A5032515801 @default.
• W2897636215 creator A5040057520 @default.
• W2897636215 creator A5040411677 @default.
• W2897636215 creator A5043855296 @default.
• W2897636215 creator A5045229449 @default.
• W2897636215 creator A5045731423 @default.
• W2897636215 creator A5054654885 @default.
• W2897636215 creator A5054816508 @default.
• W2897636215 creator A5058503646 @default.
• W2897636215 creator A5059022907 @default.
• W2897636215 creator A5062322697 @default.
• W2897636215 creator A5069303553 @default.
• W2897636215 creator A5073092502 @default.
• W2897636215 creator A5076077834 @default.
• W2897636215 creator A5079048180 @default.
• W2897636215 creator A5081083731 @default.
• W2897636215 creator A5081203691 @default.
• W2897636215 creator A5086151596 @default.
• W2897636215 creator A5089373395 @default.
• W2897636215 creator A5089882481 @default.
• W2897636215 date "2018-10-12" @default.
• W2897636215 modified "2023-10-18" @default.
• W2897636215 title "Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma" @default.
• W2897636215 cites W1572187720 @default.
• W2897636215 cites W1986924929 @default.
• W2897636215 cites W2071549499 @default.
• W2897636215 cites W2095099120 @default.
• W2897636215 cites W2107820445 @default.
• W2897636215 cites W2108206643 @default.
• W2897636215 cites W2120377900 @default.
• W2897636215 cites W2142099365 @default.
• W2897636215 cites W2149515595 @default.
• W2897636215 cites W2156824251 @default.
• W2897636215 cites W2171771895 @default.
• W2897636215 cites W2191219754 @default.
• W2897636215 cites W2221325899 @default.
• W2897636215 cites W2233614027 @default.
• W2897636215 cites W2396328865 @default.
• W2897636215 cites W2464293395 @default.
• W2897636215 cites W2466048836 @default.
• W2897636215 cites W2513443919 @default.
• W2897636215 cites W2516544744 @default.
• W2897636215 cites W2580953357 @default.
• W2897636215 cites W2623240783 @default.
• W2897636215 cites W2728057334 @default.
• W2897636215 cites W2739393823 @default.
• W2897636215 doi "https://doi.org/10.1038/s41375-018-0276-9" @default.
• W2897636215 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6484712" @default.
• W2897636215 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30315239" @default.
• W2897636215 hasPublicationYear "2018" @default.
• W2897636215 type Work @default.
• W2897636215 sameAs 2897636215 @default.
• W2897636215 citedByCount "92" @default.
• W2897636215 countsByYear W28976362152019 @default.
• W2897636215 countsByYear W28976362152020 @default.
• W2897636215 countsByYear W28976362152021 @default.
• W2897636215 countsByYear W28976362152022 @default.
• W2897636215 countsByYear W28976362152023 @default.
• W2897636215 crossrefType "journal-article" @default.
• W2897636215 hasAuthorship W2897636215A5000379341 @default.
• W2897636215 hasAuthorship W2897636215A5003034197 @default.
• W2897636215 hasAuthorship W2897636215A5005446802 @default.
• W2897636215 hasAuthorship W2897636215A5010286156 @default.
• W2897636215 hasAuthorship W2897636215A5011217358 @default.
• W2897636215 hasAuthorship W2897636215A5017461150 @default.
• W2897636215 hasAuthorship W2897636215A5018718373 @default.
• W2897636215 hasAuthorship W2897636215A5025529105 @default.
• W2897636215 hasAuthorship W2897636215A5032515801 @default.
• W2897636215 hasAuthorship W2897636215A5040057520 @default.
• W2897636215 hasAuthorship W2897636215A5040411677 @default.
• W2897636215 hasAuthorship W2897636215A5043855296 @default.
• W2897636215 hasAuthorship W2897636215A5045229449 @default.
• W2897636215 hasAuthorship W2897636215A5045731423 @default.
• W2897636215 hasAuthorship W2897636215A5054654885 @default.
• W2897636215 hasAuthorship W2897636215A5054816508 @default.
• W2897636215 hasAuthorship W2897636215A5058503646 @default.
• W2897636215 hasAuthorship W2897636215A5059022907 @default.
• W2897636215 hasAuthorship W2897636215A5062322697 @default.
• W2897636215 hasAuthorship W2897636215A5069303553 @default.
• W2897636215 hasAuthorship W2897636215A5073092502 @default.
• W2897636215 hasAuthorship W2897636215A5076077834 @default.
• W2897636215 hasAuthorship W2897636215A5079048180 @default.
• W2897636215 hasAuthorship W2897636215A5081083731 @default.
• W2897636215 hasAuthorship W2897636215A5081203691 @default.
• W2897636215 hasAuthorship W2897636215A5086151596 @default.
• W2897636215 hasAuthorship W2897636215A5089373395 @default.
• W2897636215 hasAuthorship W2897636215A5089882481 @default.
• W2897636215 hasBestOaLocation W28976362151 @default.

• next